Circuit-Bio
Platform of Logical Gene Circuits for Cancer Immunotherapy
Company Overview
Snapshot
Founded in April 2020 by Nir Skalka, Circuit-Bio operated with 1–10 employees. The company secured funding across one round from FutuRx and RMGP Biopharma Investment Fund, before ceasing operations in February 2025.
Business overview
Circuit-Bio was a synthetic biology company focused on developing a platform of logical gene circuits for cancer immunotherapy. Its core technology involved generating gene circuits that locally and accurately produce immune-stimulating proteins, exclusively expressed in targeted tumor cells. This approach aimed to convert cancer cells into an anti-tumor resource, triggering a robust and long-term immune response. The company's platform utilized synthetic cancer-specific promoters to control immunomodulator output, serving the pharmaceutical and biotechnology sectors with a focus on drug discovery and development.
Log in to access full profile ›Company Intelligence Q&A
- What is Circuit-Bio's operational status?
- Circuit-Bio is currently non-active, having ceased operations in February 2025.
- When was Circuit-Bio founded?
- Circuit-Bio was founded in April 2020.
- Who is the founder of Circuit-Bio?
- Nir Skalka is the founder and CSO of Circuit-Bio.
- What was Circuit-Bio's primary focus?
- Circuit-Bio focused on developing a platform of logical gene circuits for cancer immunotherapy, aiming to convert cancer cells into an anti-tumor resource.
- Which investors participated in Circuit-Bio's funding round?
- In September 2020, Circuit-Bio received funding from FutuRx and RMGP Biopharma Investment Fund.